You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the TAFINLAR (dabrafenib mesylate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR TAFINLAR

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for TAFINLAR

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01902173 ↗	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	Active, not recruiting	GlaxoSmithKline	Phase 1/Phase 2	2013-07-19	This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	Active, not recruiting	Novartis Pharmaceuticals	Phase 1/Phase 2	2013-07-19	This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
NCT01902173 ↗	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2013-07-19	This phase I/II trial studies the side effects and the best dose of uprosertib when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IIIC-IV cancer. Uprosertib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving uprosertib with dabrafenib and trametinib may be a better treatment for cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for TAFINLAR

Condition Name

Chart
Table

Condition Name for TAFINLAR
Intervention	Trials
Melanoma	13
Metastatic Melanoma	7
Stage IIIC Cutaneous Melanoma AJCC v7	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for TAFINLAR
Intervention	Trials
Melanoma	22
Skin Neoplasms	9
Neoplasms	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TAFINLAR

Trials by Country

Map
Table

Trials by Country for TAFINLAR
Location	Trials
United States	234
Australia	7
Germany	5
United Kingdom	3
Puerto Rico	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for TAFINLAR
Location	Trials
Massachusetts	11
Texas	10
Pennsylvania	8
California	8
Tennessee	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TAFINLAR

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for TAFINLAR
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2	18
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for TAFINLAR
Clinical Trial Phase	Trials
Recruiting	15
Active, not recruiting	12
Not yet recruiting	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TAFINLAR

Sponsor Name

Chart
Table

Sponsor Name for TAFINLAR
Sponsor	Trials
National Cancer Institute (NCI)	15
Novartis	5
Novartis Pharmaceuticals	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for TAFINLAR
Sponsor	Trials
Other	42
Industry	31
NIH	15
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.